Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.01%||176.96||0.7%||$1383.16m|
|MRK||Merck & Co., Inc.||0.66%||92.50||0.7%||$1203.71m|
|LLY||Eli Lilly & Co.||1.74%||323.14||1.1%||$1096.78m|
|BMY||Bristol-Myers Squibb Co.||-0.53%||78.28||1.0%||$1078.11m|
|TPTX||Turning Point Therapeutics, Inc.||0.32%||75.30||0.0%||$286.13m|
|HZNP||Horizon Therapeutics Plc||0.99%||82.50||5.4%||$176.10m|
|MRTX||Mirati Therapeutics, Inc.||-1.84%||67.24||1.6%||$154.95m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||0.85%||145.64||0.0%||$148.67m|
|NVO||Novo Nordisk A/S||1.63%||110.06||0.1%||$146.95m|
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.